JP2009057373A - 動物性生薬エキス配合液剤 - Google Patents
動物性生薬エキス配合液剤 Download PDFInfo
- Publication number
- JP2009057373A JP2009057373A JP2008197232A JP2008197232A JP2009057373A JP 2009057373 A JP2009057373 A JP 2009057373A JP 2008197232 A JP2008197232 A JP 2008197232A JP 2008197232 A JP2008197232 A JP 2008197232A JP 2009057373 A JP2009057373 A JP 2009057373A
- Authority
- JP
- Japan
- Prior art keywords
- extract
- caramel
- herbal
- animal
- liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 52
- 241001465754 Metazoa Species 0.000 title claims abstract description 30
- 239000003814 drug Substances 0.000 title claims abstract description 29
- 229940079593 drug Drugs 0.000 title claims abstract description 20
- 239000000284 extract Substances 0.000 claims abstract description 42
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 claims abstract description 40
- 235000013736 caramel Nutrition 0.000 claims abstract description 40
- 239000000243 solution Substances 0.000 claims abstract description 17
- 239000007864 aqueous solution Substances 0.000 claims abstract description 7
- 239000012676 herbal extract Substances 0.000 claims description 34
- 210000004185 liver Anatomy 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 6
- 241000282375 Herpestidae Species 0.000 claims description 5
- 150000002772 monosaccharides Chemical class 0.000 claims description 4
- 229940109850 royal jelly Drugs 0.000 claims description 4
- 150000005846 sugar alcohols Chemical class 0.000 claims description 4
- 235000009852 Cucurbita pepo Nutrition 0.000 claims description 2
- 239000000413 hydrolysate Substances 0.000 claims description 2
- 230000006641 stabilisation Effects 0.000 claims description 2
- 238000011105 stabilization Methods 0.000 claims description 2
- 241000219122 Cucurbita Species 0.000 claims 1
- 241000245165 Rhododendron ponticum Species 0.000 claims 1
- 238000001556 precipitation Methods 0.000 abstract description 21
- 239000000725 suspension Substances 0.000 abstract description 9
- 230000002378 acidificating effect Effects 0.000 abstract description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 36
- 239000008213 purified water Substances 0.000 description 32
- 239000003795 chemical substances by application Substances 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 150000001720 carbohydrates Chemical class 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 8
- 241000411851 herbal medicine Species 0.000 description 8
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 7
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 229960002920 sorbitol Drugs 0.000 description 7
- 241001562081 Ikeda Species 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- -1 cold medicines Substances 0.000 description 6
- 239000000600 sorbitol Substances 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 150000003868 ammonium compounds Chemical class 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 229940098465 tincture Drugs 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000003513 alkali Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 235000013379 molasses Nutrition 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 240000005528 Arctium lappa Species 0.000 description 3
- 235000003130 Arctium lappa Nutrition 0.000 description 3
- 235000008078 Arctium minus Nutrition 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 108010009736 Protein Hydrolysates Proteins 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Substances [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 235000011121 sodium hydroxide Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000208422 Rhododendron Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000003405 preventing effect Effects 0.000 description 2
- 230000003381 solubilizing effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- JVKRKMWZYMKVTQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JVKRKMWZYMKVTQ-UHFFFAOYSA-N 0.000 description 1
- WTFUTSCZYYCBAY-SXBRIOAWSA-N 6-[(E)-C-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-N-hydroxycarbonimidoyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C/C(=N/O)/C1=CC2=C(NC(O2)=O)C=C1 WTFUTSCZYYCBAY-SXBRIOAWSA-N 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 240000001980 Cucurbita pepo Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 235000011116 calcium hydroxide Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical class [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 229940124579 cold medicine Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 239000004083 gastrointestinal agent Substances 0.000 description 1
- 229940127227 gastrointestinal drug Drugs 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 150000002814 niacins Chemical class 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 150000002948 pantothenic acids Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- 229960000344 thiamine hydrochloride Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 235000019191 thiamine mononitrate Nutrition 0.000 description 1
- 239000011748 thiamine mononitrate Substances 0.000 description 1
- 229960004860 thiamine mononitrate Drugs 0.000 description 1
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/24—Mucus; Mucous glands; Bursa; Synovial fluid; Arthral fluid; Excreta; Spinal fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/407—Liver; Hepatocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Alternative & Traditional Medicine (AREA)
- Biochemistry (AREA)
- Nutrition Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Inorganic Chemistry (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Physiology (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Insects & Arthropods (AREA)
- Diabetes (AREA)
- Hematology (AREA)
Abstract
【解決手段】動物性生薬エキスを乾燥物換算量で液剤全量に対して5〜50w/v%含有し、pHが3.0〜5.5である生薬エキス配合液剤において、等電点が0.5〜4.0で、且つ1.0w/v%水溶液のpHが4.5〜6.1であるカラメルを液剤全量に対して0.5〜20w/v%配合してなる動物性生薬エキス配合液剤。
【選択図】なし
Description
1) 動物性生薬エキスを乾燥物換算量で液剤全量に対して5〜50w/v%含有し、pHが3.0〜5.5である生薬エキス配合液剤であって、等電点が0.5〜4.0で、且つ1.0w/v%水溶液のpHが4.5〜6.1であるカラメルを液剤全量に対して0.5〜20w/v%配合してなる動物性生薬エキス配合液剤。
2)動物性生薬エキスがゴオウ、シベット、ローヤルゼリー、ロクジョウ及び肝臓加水分解物から選択される一種以上の動物性生薬のエキスを含む上記1)記載の動物性生薬エキス配合液剤。
3)単糖類及び/又は糖アルコールを、液剤全量に対して1.0〜40w/v%の範囲で配合してなる上記1)又は2)の動物性生薬エキス配合液剤。
4)動物性生薬エキスを乾燥物換算量で液剤全量に対して5〜50w/v%含有し、pHが3.0〜5.5である生薬エキス配合液剤において、等電点が0.5〜4.0で、且つ1.0w/v%水溶液のpHが4.5〜6.1であるカラメルを液剤全量に対して0.5〜20w/v%配合することを特徴とする動物性生薬エキス配合液剤の安定化方法。
本発明の生薬エキスには、軟エキス、乾燥エキス、流エキス、チンキ等が包含される。
本発明のカラメルは、その等電点0.5〜4.0の範囲で、かつ且つ1.0w/v%水溶液のpHが4.5〜6.1のものである。等電点は、例えば0.5〜1.0、0.5〜2.4、0.6〜4.0等の範囲が挙げられ、0.6〜3.6であるものがより好ましく、さらに1.0w/v%水溶液のpHが4.9〜6.1であるものが好ましい。
斯かるカラメルは、市販品を用いることができ、例えば、カラメルSF(池田糖化工業(株)製)、カラメルS−W(仙波糖化工業(株)製)、カラメルKD−W(仙波糖化工業(株)製)、カラメルBCF−3(池田糖化工業(株)製)、カラメルC−85(天野実業(株)製)、カラメルSS(天野実業(株)製)、カラメルKS−W(仙波糖化工業(株)製)、カラメルFS(昭和化学工業(株)製)、カラメルFS−350S(昭和化学工業(株)製)、カラメルS(池田糖化工業(株)製)等が使用できる。
ここで、単糖類としては、フルクトース、フコース、マンノース、グルコース、ガラクトース及びリボース等が挙げられるが、特にフルクトース、グルコース及びガラクトースが好ましい。本発明で用いられる糖アルコールとしては市販のものが挙げられ、例えばエリスリトール、キシリトール、マルチトール、マンニトール、D−ソルビトール、ラクチトール、グリセロール、イノシトール及びその混液等が挙げられるが、好ましくはソルビトール又はキシリトールが挙げられる。
これらの添加剤は、例えば本発明植物性生薬エキス配合液剤において、カラメルの添加量を減量したい場合であって、減量により沈殿防止効果が減弱される場合に用いることができる。
なお、以下に示す全ての実施例、比較例は、全量を100mLとし、これらの溶液を濾過した後、ガラス試験管に充填し、キャップ閉めしたものをサンプルとして用いた。
また、カラメルの等電点は、以下の方法により求めた。
<等電点測定法>
0.5w/v%タンニン酸溶液50mLにカラメル約0.5gを溶解し、ガラス製試験管9本に各5mLずつ分注する。液が澄明な場合、0.4%塩酸または19.9%塩酸を25μLの差で累増添加し、よく混合して混濁澄明の分岐点を目視判定する。24時間室温保管後、もう一度目視観察し混濁澄明分岐点のpHを測定し、そのpHを等電点とする。カラメル溶解後の溶液が既に混濁している場合は、0.4%水酸化ナトリウムまたは16.9%水酸化ナトリウムを塩酸と同様に累増添加し、以下同じ操作を行う。例えば、混濁澄明分岐点付近の溶液pHが2.9、3.0、3.1、3.2であり、pH2.9、3.0が混濁、pH3.1、3.2が澄明な場合、等電点は3.0である。
肝臓加水分解物乾燥物換算量5.0gを室温で適量の精製水に加え十分撹拌し、これにカラメルSF(池田糖化工業(株)製、pH5.7、等電点3.1)5.0gを加え溶解する。次いで10%塩酸を用いてpHを4.0に調整し、精製水を加え全量を100mLとした(サンプル1)。
肝臓加水分解物乾燥物換算量5.0gを室温で適量の精製水に加え十分撹拌し、これにカラメルS−W(仙波糖化工業(株)製、pH5.1、等電点3.1)5.0gを加え溶解する。次いで10%塩酸を用いてpHを4.0に調整し、精製水を加え全量を100mLとした(サンプル2)。
肝臓加水分解物乾燥物換算量5.0gを室温で適量の精製水に加え十分撹拌し、これにカラメルKD−W(仙波糖化工業(株)製、pH5.1、等電点0.9)5.0gを加え溶解する。次いで10%塩酸を用いてpHを4.0に調整し、精製水を加え全量を100mLとした(サンプル3)。
肝臓加水分解物乾燥物換算量5.0gを室温で適量の精製水に加え十分撹拌し、これにカラメルBCF−3(池田糖化工業(株)製、pH5.1、等電点0.6)5.0gを加え溶解する。次いで10%塩酸を用いてpHを4.0に調整し、精製水を加え全量を100mLとした(サンプル4)。
肝臓加水分解物乾燥物換算量5.0gを室温で適量の精製水に加え十分撹拌し、これにカラメルC−85(天野実業(株)製、pH4.9、等電点2.9)5.0gを加え溶解する。次いで10%塩酸を用いてpHを4.0に調整し、精製水を加え全量を100mLとした(サンプル5)。
肝臓加水分解物乾燥物換算量5.0gを室温で適量の精製水に加え十分撹拌し、これにカラメルSS(天野実業(株)製、pH5.9、等電点3.5)5.0gを加え溶解する。次いで10%塩酸を用いてpHを4.0に調整し、精製水を加え全量を100mLとした(サンプル6)。
肝臓加水分解物乾燥物換算量5.0gを室温で適量の精製水に加え十分撹拌し、これにカラメルKS−W(仙波糖化工業(株)製、pH6.1、等電点3.6)5.0gを加え溶解する。次いで10%塩酸を用いてpHを4.0に調整し、精製水を加え全量を100mLとした(サンプル7)。
肝臓加水分解物乾燥物換算量5.0gを室温で適量の精製水に加え十分撹拌し、これにカラメルSF(池田糖化工業(株)製、pH5.7、等電点3.1)3.0g、ソルビトール20gを加え溶解する。次いで10%塩酸を用いてpHを4.0に調整し、精製水を加え全量を100mLとした(サンプル8)。
肝臓加水分解物乾燥物換算量5.0g、ゴオウチンキ乾燥物換算量3.2mg、シベットチンキ乾燥物換算量4.1mg、ロクジョウ流エキス乾燥物換算量16.7mgを室温で適量の精製水に加え十分撹拌し、これにカラメルKS−W(仙波糖化工業(株)製、pH6.1、等電点3.6)5.0gを加え溶解する。次いで10%塩酸を用いてpHを4.0に調整し、精製水を加え全量を100mLとした。
肝臓加水分解物乾燥物換算量5.0gを室温で適量の精製水に加え十分撹拌し、溶解する。次いで10%塩酸を用いてpHを4.0に調整し、精製水を加え全量を100mLとした(サンプル9)。
肝臓加水分解物乾燥物換算量5.0gを室温で適量の精製水に加え十分撹拌し、これにカラメルZ−100(仙波糖化工業(株)製、pH3.5、等電点0.4)5.0gを加え溶解する。次いで10%塩酸を用いてpHを4.0に調整し、精製水を加え全量を100mLとした(サンプル10)。
肝臓加水分解物乾燥物換算量5.0gを室温で適量の精製水に加え十分撹拌し、これにカラメルS(仙波糖化工業(株)製、pH4.3、等電点1.2)5.0gを加え溶解する。次いで10%塩酸を用いてpHを4.0に調整し、精製水を加え全量を100mLとした(サンプル11)。
肝臓加水分解物乾燥物換算量5.0gを室温で適量の精製水に加え十分撹拌し、これにカラメルKS−S(仙波糖化工業(株)製、pH6.2、等電点3.2)5.0gを加え溶解する。次いで10%塩酸を用いてpHを4.0に調整し、精製水を加え全量を100mLとした(サンプル12)。
肝臓加水分解物乾燥物換算量5.0gを室温で適量の精製水に加え十分撹拌し、これにカラメルFB(昭和化学工業(株)製、pH4.0、等電点3.4)5.0gを加え溶解する。次いで10%塩酸を用いてpHを4.0に調整し、精製水を加え全量を100mLとした(サンプル13)。
肝臓加水分解物乾燥物換算量5.0gを室温で適量の精製水に加え十分撹拌し、これにカラメルMG−18W(仙波糖化工業(株)製、pH5.3、等電点6.5)5.0gを加え溶解する。次いで10%塩酸を用いてpHを4.0に調整し、精製水を加え全量を100mLとした(サンプル14)。
肝臓加水分解物乾燥物換算量5.0gを室温で適量の精製水に加え十分撹拌し、ソルビトール40gを加え溶解する。次いで10%塩酸を用いてpHを4.0に調整し、精製水を加え全量を100mLとした(サンプル15)。
サンプル1〜7及びサンプル9〜14を用い、25℃で6箇月保存を行った。この時の、カラメル添加による生薬の経時的な沈殿又は懸濁に対する効果を観察した。結果を表1に示す。その結果、カラメルSF、カラメルS−W、カラメルKD−W、カラメルBCF−3、カラメルC−85、カラメルSS、カラメルKS−Wを加えた本発明の動物性生薬エキス配合液剤サンプル1〜7では、6箇月保存ではほとんど沈殿又は懸濁が確認されなかったが、カラメルを加えなかったサンプル9、ならびにカラメルZ−100、カラメルS、カラメルKS−S、カラメルFB、カラメルMG−18Wを加えたサンプル10〜14では、経時的な沈殿又は懸濁が確認された。
サンプル8及び15を用い、40℃で4週間保存を行った。この時の、カラメル及びソルビトール添加による生薬の経時的な沈殿又は懸濁に対する効果を観察した。結果を表2に示す。その結果、カラメルSF及びソルビトールを加えた本発明の動物性生薬エキス配合液剤サンプル8では、4週間保存ではほとんど沈殿又は懸濁が確認されなかったが、ソルビトールのみ(カラメル無添加)を加えたサンプル15では、経時的な沈殿又は懸濁が確認された。
Claims (4)
- 動物性生薬エキスを乾燥物換算量で液剤全量に対して5〜50w/v%含有し、pHが3.0〜5.5である生薬エキス配合液剤であって、等電点が0.5〜4.0で、且つ1.0w/v%水溶液のpHが4.5〜6.1であるカラメルを液剤全量に対して0.5〜20w/v%配合してなる動物性生薬エキス配合液剤。
- 動物性生薬エキスがゴオウ、シベット、ローヤルゼリー、ロクジョウ及び肝臓加水分解物から選択される一種以上の動物性生薬のエキスを含む請求項1記載の動物性生薬エキス配合液剤。
- 単糖類及び/又は糖アルコールを、液剤全量に対して1.0〜40w/v%の範囲で配合してなる請求項1又は2記載の動物性生薬エキス配合液剤。
- 動物性生薬エキスを乾燥物換算量で液剤全量に対して5〜50w/v%含有し、pHが3.0〜5.5である生薬エキス配合液剤において、等電点が0.5〜4.0で、且つ1.0w/v%水溶液のpHが4.5〜6.1であるカラメルを液剤全量に対して0.5〜20w/v%配合することを特徴とする動物性生薬エキス配合液剤の安定化方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008197232A JP4456164B2 (ja) | 2007-08-03 | 2008-07-31 | 動物性生薬エキス配合液剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007202590 | 2007-08-03 | ||
JP2008197232A JP4456164B2 (ja) | 2007-08-03 | 2008-07-31 | 動物性生薬エキス配合液剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009057373A true JP2009057373A (ja) | 2009-03-19 |
JP4456164B2 JP4456164B2 (ja) | 2010-04-28 |
Family
ID=40341079
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008197232A Active JP4456164B2 (ja) | 2007-08-03 | 2008-07-31 | 動物性生薬エキス配合液剤 |
JP2008197231A Active JP4641553B2 (ja) | 2007-08-03 | 2008-07-31 | 植物性生薬エキス配合液剤 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008197231A Active JP4641553B2 (ja) | 2007-08-03 | 2008-07-31 | 植物性生薬エキス配合液剤 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20100285147A1 (ja) |
JP (2) | JP4456164B2 (ja) |
CA (1) | CA2702711A1 (ja) |
WO (1) | WO2009019835A1 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8586106B2 (en) | 2011-12-06 | 2013-11-19 | The Concentrate Manufacturing Company Of Ireland | Fatigue-relieving herbal extracts and beverages comprising the same |
WO2013190548A2 (en) * | 2012-06-17 | 2013-12-27 | Kamedis Ltd | Topical compositions for the treatment of chronic inflammatory skin disease |
JP6760710B2 (ja) * | 2013-09-13 | 2020-09-23 | 大正製薬株式会社 | 飲料 |
US20160339086A1 (en) * | 2015-05-19 | 2016-11-24 | Suzy Cohen | Compositions and methods for treating thyroid disease |
US10702590B2 (en) | 2016-04-12 | 2020-07-07 | Script Essentials, Llc | Compositions and methods for treating thyroid disease |
CN113249354A (zh) * | 2018-09-19 | 2021-08-13 | 云南农业大学 | 齐墩果酸葡糖醛酸转移酶及其编码基因和应用 |
JP7060062B2 (ja) * | 2019-11-27 | 2022-04-26 | 大正製薬株式会社 | 経口液体組成物 |
US20220211792A1 (en) * | 2021-01-04 | 2022-07-07 | Okchundang Co., Ltd. | Composition containing natural extracts for enhancement of innate immunity or antiviral use against influenza virus or corona virus |
CN116008461A (zh) * | 2022-12-27 | 2023-04-25 | 天津现代创新中药科技有限公司 | 一种一测多评的中药膏剂检测方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5004624A (en) * | 1983-03-14 | 1991-04-02 | Star-Kist Foods, Inc. | Semi-moist pet food having free gravy and process for preparation thereof |
JP2976162B2 (ja) * | 1993-10-14 | 1999-11-10 | エスエス製薬株式会社 | 安定な複合ビタミン内服液剤 |
JPH08198762A (ja) * | 1995-01-24 | 1996-08-06 | Zeria Pharmaceut Co Ltd | 動物性生薬配合液剤 |
JPH11124328A (ja) * | 1997-10-21 | 1999-05-11 | Taisho Pharmaceut Co Ltd | アミノ酸配合内服液剤 |
WO2003024466A1 (fr) * | 2001-09-13 | 2003-03-27 | Wakunaga Pharmaceutical Co., Ltd. | Preparation liquide contenant un extrait de matieres premieres |
JP2004161679A (ja) * | 2002-11-13 | 2004-06-10 | Taiho Yakuhin Kogyo Kk | 内服用液剤 |
JP2004135686A (ja) * | 2004-02-12 | 2004-05-13 | Marubeni Nisshin Feed Co Ltd | 畜肉矯臭用飼料添加剤 |
-
2008
- 2008-07-31 WO PCT/JP2008/002054 patent/WO2009019835A1/ja active Application Filing
- 2008-07-31 CA CA2702711A patent/CA2702711A1/en not_active Abandoned
- 2008-07-31 US US12/671,865 patent/US20100285147A1/en not_active Abandoned
- 2008-07-31 JP JP2008197232A patent/JP4456164B2/ja active Active
- 2008-07-31 JP JP2008197231A patent/JP4641553B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP4641553B2 (ja) | 2011-03-02 |
JP2009057372A (ja) | 2009-03-19 |
WO2009019835A1 (ja) | 2009-02-12 |
JP4456164B2 (ja) | 2010-04-28 |
US20100285147A1 (en) | 2010-11-11 |
CA2702711A1 (en) | 2009-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4456164B2 (ja) | 動物性生薬エキス配合液剤 | |
JP2874967B2 (ja) | 本質的に水に不溶な薬剤活性体のための薬剤水懸濁液 | |
JP6282644B2 (ja) | ラセカドトリル液体組成物 | |
EP0481294B2 (de) | Feste, schnell-lösliche Arzneimittelzubereitung enthaltend N-Acetylcystein | |
JP4051717B2 (ja) | ビオチン含有内服液剤 | |
JP2818220B2 (ja) | 食品用の含水有機溶剤抽出物含有組成物および医薬用の含水有機溶剤抽出物含有組成物、並びにそれらの製造方法 | |
Fiume et al. | Safety assessment of monosaccharides, disaccharides, and related ingredients as used in cosmetics | |
JPH04159223A (ja) | 止瀉剤組成物 | |
JP2002363105A (ja) | 不快な味のマスキング方法及び内服用液剤 | |
JP2017500357A (ja) | ラセカドトリル液体組成物 | |
JP4094332B2 (ja) | 水分散性又は水溶解性のバナバ葉抽出物組成物 | |
JP3668483B2 (ja) | 生薬エキス配合液剤 | |
RU2395275C2 (ru) | Фармацевтические суспензии, не содержащие красителей, и способы их получения | |
JP2006052169A (ja) | ゾル状又はゲル状の服薬補助食品 | |
EP2134369A2 (de) | Trockenextrakte aus pelargonium sidoides und pelargonium reniforme | |
JP2004331576A (ja) | 急激な血糖値の上昇を抑制する血糖値上昇抑制剤及び食品 | |
JP5823131B2 (ja) | 防風通聖散含有組成物 | |
JPH0827034A (ja) | エリスリトール含有内用液剤 | |
CN113712982A (zh) | 一种预防或治疗非酒精性脂肪肝、肥胖症的组合物及制备方法和应用 | |
RU2778647C2 (ru) | Фармацевтическая композиция в виде водного раствора, предпочтительно сиропа, содержащая инозина пранобекс и глюконат цинка, и способ ее получения | |
JP6437183B2 (ja) | 肝機能改善剤 | |
KR20120064735A (ko) | 나테글리니드 함유 제제 | |
JP2007320885A (ja) | 固形製剤 | |
JP2906215B2 (ja) | 高濃度カルシウム含有液剤 | |
JP2008074838A (ja) | グルコシルヘスペリジン含有組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090401 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20090401 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20090422 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090519 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090721 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090724 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090818 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090819 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091117 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100105 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100126 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100204 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130212 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4456164 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130212 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130212 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130212 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140212 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |